Reinforcement of cell-mediated immunity driven by tumor-associated epstein-barr virus (ebv)-specific t cells during targeted b-cell therapy with rituximab

Frontiers in immunology(2023)

引用 3|浏览18
暂无评分
摘要
In this study, we showed for the first time that rituximab-mediated lysis of EBV-infected tumor cells can efficiently boost EBV-specific endogenous effector memory T-cell responses through cross-presentation of EBV-derived antigens. This promotes the restoration of antiviral cellular immunity and presents an efficient mechanism to improve the treatment of CD20 EBV-associated malignancies. This effect is also conceivable for other therapeutic antibodies or even for therapeutically applied unmodified or genetically modified T cells, which lead to the release of tumor antigens after specific cell lysis.
更多
查看译文
关键词
EBV+ B-LCLs,Epstein-Barr virus (EBV),cross-presentation,cytotoxic T cells (CTL),rituximab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要